Navigation Links
Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management
Date:10/29/2010

RESEARCH TRIANGLE PARK, N.C., Oct. 29 /PRNewswire/ -- Pharmaceutical Strategic Initiatives® announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.  The symposium titled Anticoagulation Management at the Crossroads –Addressing the Developments Impacting Future Decades was sponsored by Research Triangle Park, NC based Pharmaceutical Strategic Initiatives, LLC.  This interactive symposium was organized in collaboration with the Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, the North American Thrombosis Forum (NATF), and the International Union of Angiology (IUA).

Professor Jawed Fareed, Ph.D., Professor of Pathology and Pharmacology, Director of Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, was the chair for the program which also included presentations regarding emerging topics in anticoagulation management and for patients at risk of thrombosis and related disorders.  The distinguished faculty representing leading international institutions included Professor Samuel Goldhaber, MD from Brigham and Women's Hospital in Boston, MA, Professor Jeanine Walenga, Ph.D. from Loyola University Medical Center in Maywood, IL, Professor Benjamin Brenner from Rambam Health Care Campus in Haifa, Israel, Massimo Iacobelli, M.D. from Gentium, S.P.A. in Como Italy, Professor Selim Corbacioglu, M.D. from Children's Hospital Regensburg in Regensburg, Germany, Ilene Sussman, Ph.D. from the North American Thrombosis Forum in Boston, MA and Charles Carter, Pharm.D. from Pharmaceutical Strategic Initiatives, LLC in Research Triangle Park, NC.  The topics presented and discussed covered new treatment modalities for the prevention and treatment of patients at risk for thrombotic and vascular disorders including atrial fibrillation, acute coronary syndromes, diabetes, cancer and transplantation associated venous occlusive disorder.  In addition, the panel considered recent worldwide regulatory developments that are changing the landscape of anticoagulation therapy which includes the introduction of newer oral anticoagulants and generic versions of branded drugs.  The symposium was very well attended and a number of the hematology professionals who attended expressed their appreciation of this timely and informative session.

Pharmaceutical Strategic Initiatives LLC (PSI) is the premier provider of strategic clinical and regulatory consulting, priority comparative effectiveness and outcomes research, scientific content creation, opinion leader development and management to Academic Institutions, Pharmaceutical, Medical Device and Biotechnology companies. For 26 years, PSI has supported Educational Programs and Workshops, Medical Affairs, Regulatory Affairs, and Medical Marketing teams by developing successful business strategies and providing the implementation skills required to produce clear, measurable outcomes.  Charles A. Carter, Pharm.D., MBA is president of Pharmaceutical Strategic Initiatives, LLC.  PSI's offices are in Research Triangle Park, North Carolina.


'/>"/>
SOURCE Pharmaceutical Strategic Initiatives LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
3. The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment
4. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
5. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
6. Nanobiotechnology experts join forces to improve TB testing
7. Bait and Switch TV's Free Live Debates Invite TV Viewers to Debate with Experts in Real Time about Controversial Topics
8. Leading Cord Blood Experts Clarify Their Support of CORD:USE Family Cord Blood Bank
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. What's Next for Stevia? Experts from GLG Life Tech Corp Share Views on Stevia's Future at Complimentary Webinar on 17 Feb.
11. Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):